Search results for " Breast Cancer"

showing 10 items of 427 documents

Fasting renders immunotherapy effective against low-immunogenic breast cancer while reducing side effects

2022

Immunotherapy is improving the prognosis and survival of cancer patients, but despite encouraging out-comes in different cancers, the majority of tumors are resistant to it, and the immunotherapy combinations are often accompanied by severe side effects. Here, we show that a periodic fasting-mimicking diet (FMD) can act on the tumor microenvironment and increase the efficacy of immunotherapy (anti-PD-L1 and anti-OX40) against the poorly immunogenic triple-negative breast tumors (TNBCs) by expanding early exhausted effector T cells, switching the cancer metabolism from glycolytic to respiratory, and reducing collagen depo-sition. Furthermore, FMD reduces the occurrence of immune-related adve…

Tumor MicroenvironmentHumansTriple Negative Breast NeoplasmsFastingImmunotherapySettore MED/08 - Anatomia PatologicaGlycolysisnutrition triple-negative breast cancer CP: Cancer CP: Immunology fasting fasting-mimicking diet immunotherapy inflammationB7-H1 AntigenGeneral Biochemistry Genetics and Molecular BiologyCell Reports
researchProduct

Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility

2017

The importance of the immune system as a potent anti-tumor defense has been consolidated in recent times, and novel immune-related therapies are today demonstrating a strong clinical benefit in the setting of several solid neoplasms. Tumor-infiltrating lymphocytes reflect the attempt of the host to eradicate malignancies, and during the last decades, they have been shown to possess an interesting prognostic utility for breast cancer, especially in case of HER2 positive and triple-negative molecular subtypes. In parallel, the clinical evaluation of tumor-infiltrating lymphocytes has been shown to effectively predict treatment outcomes in both neoadjuvant and adjuvant settings. Currently, tu…

Tumor-infiltrating lymphocytes; breast cancer; cancer immunotherapy0301 basic medicineOncologyCA15-3medicine.medical_specialtymedicine.medical_treatmentCA 15-3Tumor-infiltrating lymphocyteBreast NeoplasmsTumor-infiltrating lymphocytes03 medical and health sciencesLymphocytes Tumor-Infiltratingbreast cancer0302 clinical medicineImmune systemBreast cancerCancer immunotherapyInternal medicinemedicineHumansRC254-282cancer immunotherapyTumor-infiltrating lymphocytesbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancerGeneral MedicinePrognosismedicine.diseaseNeoadjuvant TherapyTreatment Outcome030104 developmental biologyImmunoediting030220 oncology & carcinogenesisFemalebusinessTumor Biology
researchProduct

Synthesis of curcumin derivatives and analysis of their antitumor effects in triple negative breast cancer (TNBC) cell lines

2019

We analyzed antitumor effects of a series of curcumin analogues. Some of them were obtained by reaction of substitution involving the two phenolic OH groups of curcumin while the analogues with a substituent at C-4 was prepared following an original procedure that regards the condensation of benzenesulfenic acid onto the nucleophilic central carbon of the curcumin skeleton. We analyzed cytotoxic effects of such derivatives on two TNBC (triple negative breast cancer) cell lines, SUM 149 and MDA-MB-231, but only three of them showed an IC50 in a lower micromolar range with respect to curcumin. We also focused on these three derivatives that in both cell lines exhibited a higher or at least eq…

antiproliferative activitySubstituentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441antioxidant activityprooxidant activitylcsh:Pharmacy and materia medicapro-apoptotic activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoveryCytotoxic T cellNF-κB inhibitionAntioxidant activity Antiproliferative activity NF-κB inhibition Pro-apoptotic activity Prooxidant activity Sulfenic acidIC50Triple-negative breast cancer030304 developmental biology0303 health sciencesCommunicationlcsh:Rsulfenic acidchemistryCell culture030220 oncology & carcinogenesisCancer researchCurcuminSettore BIO/14 - FarmacologiaMolecular MedicineSulfenic acidLead compound
researchProduct

Effect of Combining Impact-Aerobic and Strength Exercise, and Dietary Habits on Body Composition in Breast Cancer Survivors Treated with Aromatase In…

2023

This study examines both the effect of a twice-weekly combined exercise—1 h session of strength and 1 h session of impact-aerobic—on body composition and dietary habits after one year of treatment with aromatase inhibitors (AI) in breast cancer survivors. Overall, forty-three postmenopausal women with a BMI ≤ 35 kg/m2, breast cancer survivors treated with AI, were randomized into two groups: a control group (CG) (n = 22) and a training group (IG) (n = 21). Body composition, i.e., abdominal, visceral, and subcutaneous adipose tissue) was measured by magnetic resonance. In addition, some questionnaires were used to gather dietary data and to measure adherence to the Mediterranean diet. After …

body compositionnaisetrintasyöpäbreast cancer survivorscombined exerciseHealth Toxicology and Mutagenesisstrength exercisePublic Health Environmental and Occupational Healthruokavaliotaromatase inhibitorscombined exercise; impact-aerobic exercise; strength exercise; dietary habits; body composition; aromatase inhibitors; breast cancer survivorsravintoterveysvaikutuksetimpact-aerobic exercisevoimaharjoitteludietary habitskehonkoostumusInternational Journal of Environmental Research and Public Health; Volume 20; Issue 6; Pages: 4872
researchProduct

Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Neg…

2015

BC-11 is an easily synthesized simple thiouronium-substituted phenylboronic acid, which has been shown to be cytotoxic on triple negative MDA-MB231 breast cancer cells by inducing a perturbation of cell cycle when administered at a concentration equal to its ED50 at 72 h (117 μM). Exposure of cells to BC-11, either pre-absorbed with a soluble preparation of the N-terminal fragment of urokinase-plasminogen activator (uPa), or in co-treatment with two different EGFR inhibitors, indicated that: (i) BC-11 acts via binding to the N-terminus of the enzyme where uPa- and EGF receptor-recognizing sites are present, thereby abrogating the growth-sustaining effect resulting from receptor binding

boronic acidPharmaceutical ScienceGene ExpressionApoptosisAnalytical ChemistryDrug DiscoveryCytotoxic T cellSettore BIO/06 - Anatomia Comparata E CitologiaCytotoxicityEGFR inhibitorschemistry.chemical_classificationCell CycleDrug SynergismCell cycleBoronic AcidsMitochondriaErbB ReceptorsBiochemistryChemistry (miscellaneous)Molecular MedicinecytotoxicityFemaleQD0241Antineoplastic AgentsArticlelcsh:QD241-441plasminogen activator inhibitorbreast cancerlcsh:Organic chemistryCell Line TumorHumansPhysical and Theoretical ChemistryMammary Glands HumanCell ProliferationQD0415Reactive oxygen speciesHydrobromideOrganic ChemistryEpithelial CellsBC-11Molecular biologyUrokinase-Type Plasminogen ActivatorPlasminogen InactivatorsEnzymechemistryApoptosisQuinazolinesMDA-MB231 cellsReactive Oxygen Speciesboronic acid; BC-11; plasminogen activator inhibitor; breast cancer; cytotoxicity; MDA-MB231 cellsMolecules
researchProduct

The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs

2021

Breast cancer (BC) mortality is mainly due to metastatic disease, which is primarily driven by cancer stem cells (CSC). The chemokine C-X-C motif ligand-1 (CXCL1) is involved in BC metastasis, but the question of whether it regulates breast cancer stem cell (BCSC) behavior is yet to be explored. Here, we demonstrate that BCSCs express CXCR2 and produce CXCL1, which stimulates their proliferation and self-renewal, and that CXCL1 blockade inhibits both BCSC proliferation and mammosphere formation efficiency. CXCL1 amplifies its own production and remarkably induces both tumor-promoting and immunosuppressive factors, includingSPP1/OPN,ACKR3/CXCR7,TLR4,TNFSF10/TRAILandCCL18and, to a lesser exte…

breast cancer stem cellsQH301-705.5animal diseasesSettore MED/50 - Scienze Tecniche Mediche ApplicatechemokinesBiologyCXCR4MetastasisCell and Developmental Biologyimmunity geneCancer stem cellmedicinetumor microenvironmentCXC chemokine receptorsBiology (General)immunity genesTriple-negative breast cancerTumor microenvironmentbreast cancer stem cellchemokineCell BiologyBrief Research Reportrespiratory systemmedicine.diseaseCXCL1Tumor progressiontriple-negative breast cancerCancer researchCCL28Settore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Krūts vēža attīstība Latvijā pēc valsts krūts vēža skrīninga programmas ieviešanas

2020

Latvijā sieviešu saslimstība un mirstība no krūts vēža ieņem pirmo vietu starp visiem ļaundabīgiem audzējiem. Katru gadu saslimšana tiek pirmreizēji reģistrēta aptuveni 1100 pacientēm un ikgadu no krūts vēža mirst vairāk nekā 400 sievietes. Kopš 2009. gadā Latvijā darbojas valsts krūts vēža skrīnings ar mērķi uzlabot krūts vēža agrīnu diagnostiku, tomēr vidēji 32 % gadījumos krūts vēzis tiek diagnosticēts novēloti slimības III un IV stadijā (SPKC, 2017). Darba tēma ir aktuāla un darba rezultāti ļauj sniegt rekomendācijas agrīnas diagnostikas uzlabošanai un skrīninga programmas uzlabošanai. Darba mērķis: veikt Latvijas valsts apmaksāta krūšu skrīninga efektivitātes izpēti laika posmā no 2010…

breast cancer breast cancer screening effectiveness.efektivitātekrūts vēziskrūts vēža skrīningsMedicīna
researchProduct

Identification and analysis of tumor-associated antigens in triple-negative breast cancer (TNBC)

2020

business.industryCancer researchMedicineIdentification (biology)businessTumor associated antigenTriple-negative breast cancerGeburtshilfe und Frauenheilkunde
researchProduct

Cadmium effect on gene expression by MDA-MB231 breast cancer cells: evidence for down-regulation of AEG-1

2006

cadmium breast cancer gene expressionSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct

MiR-221 promotes stemness of breast cancer cells by targeting DNMT3b

2016

// Giuseppina Roscigno 1, 2 , Cristina Quintavalle 1, 2 , Elvira Donnarumma 3 , Ilaria Puoti 1 , Angel Diaz-Lagares 4 , Margherita Iaboni 1 , Danilo Fiore 1 , Valentina Russo 1 , Matilde Todaro 5 , Giulia Romano 6 , Renato Thomas 7 , Giuseppina Cortino 7 , Miriam Gaggianesi 5 , Manel Esteller 4 , Carlo M. Croce 6 , Gerolama Condorelli 1, 2 1 Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Naples, Italy 2 IEOS-CNR, Naples, Italy 3 IRCCS-SDN, Naples, Italy 4 Epigenetic and Cancer Biology Program (PEBC) IDIBELL, Hospital Duran I Reynals, Barcelona, Spain 5 Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Lab…

cancer stem cells0301 basic medicineMicro RNAsCellular differentiationADNDNMTStem cellsStem cell markermedicine.disease_causeBioinformaticsMCF-7 Cell0302 clinical medicineBreast cancerHEK293 CellTumor Cells CulturedDNA (Cytosine-5-)-MethyltransferasesOligonucleotide Array Sequence AnalysisMicroscopy ConfocalReverse Transcriptase Polymerase Chain ReactionMicroRNAHomeodomain ProteinNanog Homeobox ProteinmicroRNAsGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMCF-7 CellsNeoplastic Stem CellsRNA InterferenceCèl·lules mareBreast NeoplasmResearch PaperHumanHomeobox protein NANOGBlotting WesternBreast NeoplasmsBiologyCàncer de mama03 medical and health sciencesmicroRNAs breast cancer cancer stem cells DNMTBreast cancerCancer stem cellCell Line TumorSpheroids CellularmedicineHumansHomeodomain ProteinsOligonucleotide Array Sequence AnalysiCancer stem cellGene Expression ProfilingCancerDNAmedicine.diseaseMolecular medicineMicroRNAsHEK293 Cells030104 developmental biologyDNA (Cytosine-5-)-MethyltransferaseCancer researchNeoplastic Stem CellCarcinogenesisOctamer Transcription Factor-3
researchProduct